Drugs / indisulam
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00060567 | Mar 2003 → Mar 2013 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00003981 | Apr 1998 → ? | cancer of unknown primary site | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 1 | NCT00003976 | Mar 1998 → ? | cancer of unknown primary site | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00165594 | Feb 2005 → Jul 2006 | gastric cancer | Eisai Inc. | Terminated | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT01692197 | Feb 2013 → Jun 2017 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00165867 | Apr 2005 → ? | colorectal cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00165880 | Dec 2004 → Sep 2007 | breast cancer | Eisai Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00080197 | Feb 2004 → May 2005 | breast cancer, metastatic carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00165854 | Mar 2003 → ? | colorectal cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00059735 | May 2002 → Dec 2003 | renal cell adenocarcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00014625 | Feb → Nov 2001 | cutaneous melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Indisulam | “An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With...” NCT00165867 ↗4“An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine” NCT00165880 ↗ |
| Known as | E7070 | “An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine” NCT00165880 ↗ |
| Modality | Small molecule | — CHEMBL77517 ↗ |
| Route | Intravenous | “Patients receive E7070 IV over 1 hour once every 3 weeks.” NCT00003976 ↗ |